Fulcrum Therapeutics, Inc. (FULC)

Over the past six months, Fulcrum Therapeutics' stock price has been impacted by several events. The company reported its Q3 2025 earnings on October 29, 2025, with an EPS of ($0.31), missing analysts' consensus estimates. As of February 25, 2025, Fulcrum was progressing in its Phase 1b PIONEER trial for pociredir in sickle cell disease, with data from the 12 mg dose cohort expected by mid-2025 and from the 20 mg cohort by year-end 2025. On January 12, 2026, JPMorgan Chase & Co. initiated coverage on Fulcrum Therapeutics with an "overweight" rating and a $20.00 price target. The stock experienced a significant increase of 181.63% between February 3, 2025, and January 30, 2026, with the share price rising from $3.81 to $10.73. On February 2, 2026, CEO Alex Sapir received a stock option to buy 650,000 shares at an exercise price of $10.72 per share, vesting over four years. Collaboration revenue for the year ended December 31, 2024, was $80.0 million, a significant increase from $2.8 million in 2023, primarily due to an $80.0 million upfront license payment received from Sanofi during 2024.

Based on the provided search results, there is no specific information available regarding demand seasonality for Fulcrum Therapeutics, Inc.'s products and services. The company is a clinical-stage biopharmaceutical company, meaning its primary focus is on the development of new medicines rather than the commercial sale of established products that might exhibit seasonal demand patterns.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for genetically defined diseases. Their lead product candidates include Losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and Pociredir for sickle cell disease (SCD) and beta-thalassemia. The company also discovers drug targets for inherited aplastic anemias, novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies, utilizing proprietary technology to modulate gene expression.

Fulcrum Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, and focuses on developing medicines for patients with genetically defined diseases in the United States. There is no specific information available regarding an international geographic footprint or market reach beyond the U.S.

Fulcrum Therapeutics generally holds a positive to neutral brand reputation among analysts. The stock has received a consensus rating of "Buy" from some analysts and "Hold" from others. MarketBeat's MarketRank™ scored Fulcrum Therapeutics higher than 58% of companies evaluated and ranked it 434th out of 872 stocks in the medical sector. There were no specific events identified in the provided search results that negatively impacted Fulcrum Therapeutics' brand reputation in the past year, beyond the general fluctuations associated with clinical-stage biopharmaceutical companies and their earnings reports.

Fulcrum Therapeutics, Inc. has a substantial institutional ownership base, with institutional investors holding 84.38% of the shares as of January 2026. Insiders decreased their holdings from 3.52% to 3.46%. Major institutional owners and shareholders include RA Capital Management, L.P., Suvretta Capital Management, LLC, TCG Crossover Management, LLC, Nantahala Capital Management, LLC, BlackRock, Inc., Vanguard Group Inc., Adage Capital Partners Gp, L.l.c., and D. E. Shaw & Co., Inc.